Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556088 · ClinicalTrials.gov registry record · Phase 1
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00556088 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 40 participants.
The verdict
NCT00556088, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase I protocol will evaluate the safety and tolerability of the combination of LBH589 and paclitaxel/carboplatin. The combination of LBH589, paclitaxel/carboplatin, and bevacizumab will also be evaluated for tolerability and preliminary antitumor activity in a subset of patients with advanced non-small cell lung cancer.
Interventions
- DRUG LBH589, Paclitaxel, Carboplatin, Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556088
The ClinicalTrials.gov registry entry for NCT00556088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589, Paclitaxel, Carboplatin, Bevacizumab is the first listed.
NCT00556088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00556088 about?
NCT00556088 is a clinical study titled "LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors". This phase I protocol will evaluate the safety and tolerability of the combination of LBH589 and paclitaxel/carboplatin. The combination of LBH589, paclitaxel/carboplatin, and bevacizumab will also be evaluated for tolerability and preliminary antitumor activity in a subset of patients with advanced...
What is the current status of trial NCT00556088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00556088?
The interventions under investigation include: LBH589, Paclitaxel, Carboplatin, Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00556088?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.